Transplantační medicína

EREDMÉNYEK, AMELYEKET A DUPIXENT-TEL KEZELT BETEGEK TAPASZTALHATNAK

We are pleased to share with you information on ‘Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis,’ together with the ‘Guidelines of Care for the Management of Atopic Dermatitis in Pediatric Patients.’ We believe these publications may be of interest to you.

This email highlights key evidence regarding dupilumab, including its long-term safety and efficacy profile in infants and young children with atopic dermatitis. It also presents current guideline recommendations, which strongly support the use of dupilumab in children aged 6 months and older with moderate-to-severe atopic dermatitis.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.